TIAA Trust National Association Sells 1,488 Shares of Stryker Co. (NYSE:SYK)

TIAA Trust National Association lowered its position in Stryker Co. (NYSE:SYK - Free Report) by 3.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,265 shares of the medical technology company's stock after selling 1,488 shares during the period. TIAA Trust National Association's holdings in Stryker were worth $15,578,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. J. W. Coons Advisors LLC raised its position in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC lifted its stake in Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after acquiring an additional 27 shares during the period. Opal Wealth Advisors LLC grew its stake in shares of Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares during the period. Lindbrook Capital LLC lifted its position in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after purchasing an additional 28 shares during the period. Finally, Alhambra Investment Management LLC boosted its holdings in Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock worth $719,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts have recently weighed in on SYK shares. The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Wells Fargo & Company boosted their price target on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC restated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Stryker Price Performance

SYK stock traded down $3.16 during trading on Friday, hitting $364.38. 1,274,307 shares of the company's stock traded hands, compared to its average volume of 1,289,456. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a market capitalization of $139.08 billion, a price-to-earnings ratio of 46.96, a P/E/G ratio of 2.93 and a beta of 0.95. The business has a fifty day simple moving average of $384.08 and a 200 day simple moving average of $374.32. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's dividend payout ratio is presently 43.30%.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.